Singapore markets close in 6 hours 26 minutes

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
38.96+1.00 (+2.63%)
At close: 04:00PM EDT
38.87 -0.09 (-0.24%)
After hours: 06:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close37.96
Open37.98
Bid38.95 x 100
Ask48.93 x 200
Day's range37.65 - 39.06
52-week range15.50 - 52.57
Volume583,115
Avg. volume577,583
Market cap2.376B
Beta (5Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Rhythm Pharmaceuticals Announces New Employment Inducement Grants

    BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees. These inducement RSUs are subjec

  • GlobeNewswire

    Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

    -- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial evaluating setmelanotide in hypothalamic obesity remains on track for topline data readout in 1H 2025; dosing of first patients in Japan anticipated in 2Q 2024 -- -- Secured $150 million in convertible preferred stock financ

  • GlobeNewswire

    Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

    -- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS -- -- Company remains on track to complete submission of sNDA to the FDA seeking a label expansion for pediatric patients in 1H 2024 -- -- Two additional posters presented at PES 2024 -- BOSTON, May 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, In